Table 3.
Comparison of Outcomes Between the 2 Groups. a
| Characteristic | Group 1 | Group 2 | P Value |
|---|---|---|---|
| (n = 52) | (n = 22) | ||
| Mean logMAR BCVA ± SD | |||
| POD 15 | 1.1 ± 0.5 | 0.8 ± 0.5 | .004 |
| POD 90 | 0.9 ± 0.5 | 0.7 ± 0.5 | .002 |
| Final follow-up | 0.8 ± 0.5 | 0.7 ± 0.5 | .0006 |
| Mean BCVA improvement vs baseline ± SD | |||
| POD 15 | 0.6 ± 0.6 | 0.2 ± 0.2 | .004 |
| POD 90 | 0.8 ± 0.7 | 0.3 ± 0.3 | .002 |
| Final follow-up | 0.8 ± 0.6 | 0.3 ± 0.2 | .0005 |
| Mean IOP (mm Hg) ± SD | |||
| POD 15 | 21.0 ± 8.9 | 18.4 ± 5.3 | .064 |
| Final follow-up | 20.2 ± 7.7 | 16.5 ± 4.3 | .006 |
| IOP ≥21 mm Hg b at final follow-up, n (%) | 5 (9.6) | 4 (18.2) | .303 |
| Snellen BCVA better than 6/60, n (%) | 26 (50.0) | 12 (54.5) | .721 |
| Silicone oil removal, n (%) | .546 | ||
| Yes | 39 (75.0) | 15 (68.2) | |
| Not until last follow-up/recurrent RD | 13 (25.0) | 7 (31.8) | |
| Final retina status, n (%) | .33 | ||
| Macula-on | 43 (82.69) | 16 (72.72) | |
| Recurrent RD, macula-on | 2 (3.84) | 2 (9.10) | |
| Recurrent RD, macula-off | 7 (13.46) | 4 (18.18) | |
Abbreviations: BCVA, best-corrected visual acuity; IOP, intraocular pressure; POD, postoperative day; RD, retinal detachment.
a
Group 1 patients received short-term tamponade with perfluoro-N-octane. Group 2 patients received tamponade with silicone oil.
b
With or without antiglaucoma medication.